Top

Published in:

Open Access 01-12-2014 | Case report

Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report

Authors: Maria Giuseppa Vitale, Ferdinando Riccardi, Carmela Mocerino, Carmela Barbato, Roberto Monaco, Paola Galloro, Nicola Gagliardi, Giacomo Cartenì

Published in: Journal of Medical Case Reports | Issue 1/2014

Abstract

Introduction

The efficacy of erlotinib in advanced non-small-cell lung cancer has been demonstrated in several trials, but only two cases of complete and prolonged response in wild-type epidermal growth factor receptor locally advanced lung cancer have been published.

Case presentation

We discuss a case of a 67-year-old Caucasian man, a former heavy cigarette smoker, with a diagnosis of wild-type epidermal growth factor receptor locally advanced adenocarcinoma. After platinum-based doublet chemotherapy, when a progression of disease had occurred, a second-line therapy with erlotinib was started. We observed a progressive reduction of his lung lesion during erlotinib treatment until there was a complete clinical response.

Conclusions

This case is interesting for the choice of second-line treatment in non-small-cell lung cancer and, moreover, for the possibility of a complete and prolonged response to erlotinib even in patients without the activating mutation of epidermal growth factor receptor.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed

Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012, 23 (Suppl 7): vii56-vii64.CrossRefPubMed

Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12: 735-742. 10.1016/S1470-2045(11)70184-X.CrossRefPubMed

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lungcancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13: 239-246. 10.1016/S1470-2045(11)70393-X.CrossRefPubMed

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L: National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005, 353: 123-132. 10.1056/NEJMoa050753.CrossRefPubMed

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G, SATURNinvestigators: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11 (6): 521-529. 10.1016/S1470-2045(10)70112-1.CrossRefPubMed

Seer.cancer.gov [Internet]. Bethesda: Surveillance Epidemiology and End Results (SEER), Inc, [cited 2010 Oct]. Available from: http://www.seer.cancer.gov

Burdett S, Stewart L, Pignon JP: Chemotherapy in non–small cell lung cancer: an update of an individual patient data-based meta-analysis. J Thorac Cardiovasc Surg. 2005, 129: 1205-CrossRefPubMed

Burdett S, Stephens R, Stewart L, Tierney J, Auperin A, Le Chevalier T, Le Pechoux C, Pignon JP, Arriagada R, Higgins J, Johnson D, van Meerbeeck J, Parmar M, Souhami R, Bell D, Cartei G, Cormier Y, Cullen M, Ganz P, Gridelli C, Kaasa S, Quoix E, Rapp E, Seymour L, Spiro S, Thatcher N, Tummarello D, Williams C, Williamson I, NSCLC Meta analyses collaborative group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008, 26: 4617-4625.CrossRef

10.

Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F: Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist. 2007, 12: 840-849. 10.1634/theoncologist.12-7-840.CrossRefPubMed

11.

Wang F, Fu S, Shao Q, Zhou YB, Zhang X, Zhang X, Xue C, Lin JG, Huang LX, Zhang L, Zhang WM, Shao JY: High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. J Transl Med. 2013, 11: U1-U10. 10.1186/1479-5876-11-1.CrossRef

12.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005, 23: 8081-8092. 10.1200/JCO.2005.02.7078.CrossRefPubMed

13.

Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, Ayoub J, Lago S, de Albuquerque Ribeiro R, Gerogianni A, Cyjon A, Noble J, Laberge F, Chan RT, Fenton D, von Pawel J, Reck M, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group Study BR.21: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2007, 24: 3831-3837.CrossRef

14.

Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar , Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004, 22: 1589-1597. 10.1200/JCO.2004.08.163.CrossRefPubMed

15.

Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000, 18: 2095-2103.PubMed

16.

Clark GM, Zborowski D, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd F, National Cancer Institute of Canada Clinical Trials Group: Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. J Clin Oncol. 2005, 23 (16 suppl): 374s-

17.

Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D: Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study. J Thorac Oncol. 2010, 5 (10): 1616-1622. 10.1097/JTO.0b013e3181f1c7b0.CrossRefPubMed

18.

Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012, 13: 300-308. 10.1016/S1470-2045(11)70385-0.CrossRefPubMed

19.

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S, TAILOR trialists: Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013, 14: 981-988. 10.1016/S1470-2045(13)70310-3.CrossRefPubMed

20.

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer. 2012, 78: 8-15. 10.1016/j.lungcan.2012.06.009.CrossRefPubMed

21.

Karam I, Melosky B: Response to second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer: make no assumptions. Curr Oncol. 2012, 19: 42-46.CrossRefPubMedPubMedCentral

22.

Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N: A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2012, 69: 1241-1246. 10.1007/s00280-012-1831-0.CrossRefPubMed

Title: Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report
Authors: Maria Giuseppa Vitale
Ferdinando Riccardi
Carmela Mocerino
Carmela Barbato
Roberto Monaco
Paola Galloro
Nicola Gagliardi
Giacomo Cartenì
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Medical Case Reports / Issue 1/2014
Electronic ISSN: 1752-1947
DOI: https://doi.org/10.1186/1752-1947-8-102

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report

Abstract

Introduction

Case presentation

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Gemcitabine-induced cardiomyopathy: a case report and review of the literature

Metastasis of gastrointestinal stromal tumor to skeletal muscle: a case report

Radical excision combined with instrumented fixation in the management of thoracic epidural angiolipoma: a case report

Bilateral endogenous Fusarium solani endophthalmitis in a liver-transplanted patient: a case report

Breast and splenic metastases of squamous cell carcinoma from the uterine cervix: a case report

Hypomelanosis of Ito with a trisomy 2 mosaicism: a case report